Evidence map›Paper›PMID 39854524›Full record

ArticlePloS one2025

Psychometric validation of the Cystic Fibrosis Impact Questionnaire (CF-IQ): A patient-reported outcome assessing impacts of cystic fibrosis.

Daniel Serrano, Alyssa Uzumcu, Maya Gerstein, Nicolai D Ayasse, Ella Engstrom, Frederick B Barnes, Charles Iaconangelo, Teja Thorat, Lisa J McGarry, Isabelle Sermet-Gaudelus

Abstract readValidation Study
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniel SerranoPharmerit International-An OPEN Health Company, Bethesda, MD, United States of America.ORCID 0009-0007-6018-1367
Alyssa UzumcuPharmerit International-An OPEN Health Company, Bethesda, MD, United States of America.
Maya GersteinPharmerit International-An OPEN Health Company, Bethesda, MD, United States of America.
Nicolai D AyassePharmerit International-An OPEN Health Company, Bethesda, MD, United States of America.ORCID 0000-0003-0890-7742
Ella EngstromPharmerit International-An OPEN Health Company, Bethesda, MD, United States of America.
Frederick B BarnesPharmerit International-An OPEN Health Company, Bethesda, MD, United States of America.
Charles IaconangeloPharmerit International-An OPEN Health Company, Bethesda, MD, United States of America.
Teja ThoratVertex Pharmaceuticals Incorporated, Boston, MA, United States of America.
Lisa J McGarryVertex Pharmaceuticals Incorporated, Boston, MA, United States of America.
Isabelle Sermet-GaudelusINSERM U1151, Université Paris Cité, Centre de Références Maladies Rares Mucoviscidose et Maladies Apparentées, Hôpital Necker Enfants Malades, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Cystic Fibrosis (CF) Impact Questionnaire (CF-IQ) was qualitatively developed to assess the impact of CF in the context of treatment advancements and increased longevity. This study reports the CF-IQ validation. In this noninterventional validation study, people with CF completed the 40-item CF-IQ and validating patient-reported outcome measures (PROMs) via electronic diaries at enrollment (baseline) and at the 4-week follow-up. Validation consisted of modern methods and focus groups to finalize structural validity, and classical methods to assess internal consistency [1-3], test-retest reliability [4,5], concurrent validity [5], and known-groups validity [5] of the CF-IQ. At baseline, 214 adults completed the survey; 193 completed the follow-up survey. Unidimensional item response theory (IRT) models were separately fit to 5 prespecified domains (Control and Burden of CF Treatment Impacts, Physical Activity Impacts, Social Activity Impacts, Emotional Impacts, and Work/School Limitation Impacts). IRT local dependence (LD) statistics identified 17 redundant items. Two independent CF-patient focus groups (14 total patients) confirmed these findings, and the 17 items were dropped. Each domain defined on the final 23 items achieved the criterion of exact model fit as measured by the root mean squared error of approximation (RMSEA, values = 0), Internal consistency (Cronbach's α) values ranged from 0.81 to 0.89, 4 of 5 domains achieved acceptable test-retest reliability, with intraclass correlation coefficient (ICC) values ≥ 0.7, acceptable concurrent validity was achieved for all domains, and known-groups validity was established. The novel CF-IQ is a psychometrically robust PROM capturing patient-centric impacts of CF in the context of the current standard of care.

Indexed as

Cystic FibrosisPatient Reported Outcome MeasuresPsychometricsAdolescentAdultFemaleFocus GroupsHumansMaleMiddle AgedQuality of LifeReproducibility of ResultsSurveys and QuestionnairesYoung Adult

Identifiers

PMID39854524
PMCPMC11761112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.